login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
SUMMIT THERAPEUTICS INC (SMMT) Stock News
NASDAQ:SMMT -
US86627T1088
-
Common Stock
26.12
USD
-0.08 (-0.31%)
Last: 8/25/2025, 10:29:59 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SMMT Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Benzinga
- Mentions:
ISRG
TEVA
LLY
MDT
...
10 Health Care Stocks With Whale Alerts In Today's Session
6 days ago - By: Zacks Investment Research
- Mentions:
MRK
MRNA
Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
8 days ago - By: The Motley Fool
- Mentions:
LLY
VRTX
3 Fantastic Growth Stocks to Buy in August
11 days ago - By: Summit Therapeutics
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
12 days ago - By: Yahoo Finance
Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call
13 days ago - By: Zacks Investment Research
- Mentions:
PFE
MRK
CRMD
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
14 days ago - By: Summit Therapeutics
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
14 days ago - By: Zacks Investment Research
- Mentions:
MRK
MRNA
VRNA
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
a month ago - By: The Motley Fool
- Mentions:
CRSP
VKTX
VRTX
3 Monster Stocks in the Making to Buy Right Now
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
a month ago - By: Benzinga
- Mentions:
JAZZ
JNJ
MRK
UNH
...
10 Health Care Stocks Whale Activity In Today's Session
a month ago - By: The Schall Law Firm
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
2 months ago - By: Yahoo Finance
- Mentions:
AZN
9926
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal
2 months ago - By: Zacks Investment Research
- Mentions:
AZN
BMY
MRK
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
2 months ago - By: Yahoo Finance
- Mentions:
AZN
9926
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
2 months ago - By: Yahoo Finance
- Mentions:
AZN
Why AstraZeneca Stock Got Thumped on Thursday
2 months ago - By: Bloomberg
Summit Is in Talks for $15 Billion Partnership With AstraZeneca
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Please enable JavaScript to continue using this application.